Cat. No. 3627
Chemical Name: [3-[[3-(2-Amino-2-oxoethyl)-2-ethyl
Biological ActivitySelective secreted phospholipase A2 (sPLA2) inhibitor (IC50 values are <1 μM for group IIA and <50 μM for group V). Attenuates VEGF-mediated platelet-activating factor (PAF) synthesis in BAEC and HUVEC cells at a concentration of 100 μM.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Bernatchez et al (2001) VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2. Br.J.Pharmacol. 134 197. PMID: 11522612.
Bridonneau et al (1997) High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2). J.Med.Chem 41 778.
Schevitz et al (1995) Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat.Struct.Biol. 2 429. PMID: 7664101.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for LY 311727 include:
Mock et al (2013) Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer. Integr Biol (Camb) 5 172. PMID: 22890797.
Do you know of a great paper that uses LY 311727 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LY 311727, supplier, LY311727, secreted, phospholipases, a2, sPLA2, PLA2, inhibitors, inhibits, Tocris Bioscience, Phospholipase Inhibitor products